Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A slow-growing malignant bone tumor arising from the remnants of the notochord and occurring in the spine. It is characterized by a lobulated growth pattern, myxoid stroma formation, and the presence of physaliphorous cells.
Biomarker and diagnostic research for spinal chordoma has been reported in the published literature.
2 clinical trials registered, 1 recruiting. Interventions under study include other interventions and procedural interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
153 publications have been identified in PubMed for spinal chordoma. Research spans Case Report / Case Series (25%), Review / Meta-Analysis (20%), and Basic Science / Preclinical (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 38 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:43 AM UTC
Research summaries | 30 | 20% |
Laboratory research | 27 | 18% |
Disease patterns and progression | 22 | 14% |
Clinical study results | 20 | 13% |
Testing and diagnosis research | 10 | 7% |
Other research | 3 | 2% |
New treatment approaches | 3 | 2% |
Tsuchiya R (2026). [PMID: 40231408](https://pubmed.ncbi.nlm.nih.gov/40231408/). *Spine*. [Review / Meta-Analysis]
Godoy IRB (2026). [PMID: 41217469](https://pubmed.ncbi.nlm.nih.gov/41217469/). *Skeletal Radiol*. [Diagnostic / Biomarker]
Suzuki T (2026). [PMID: 42027880](https://pubmed.ncbi.nlm.nih.gov/42027880/). *J Toxicol Pathol*. [Case Report / Case Series]
Hajikarimloo B (2026). [PMID: 40515835](https://pubmed.ncbi.nlm.nih.gov/40515835/). *European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society*. [Review / Meta-Analysis]
He G (2026). [PMID: 42013471](https://pubmed.ncbi.nlm.nih.gov/42013471/). *Spine (Phila Pa 1976)*. [Other]
Pipola V (2026). [PMID: 42237047](https://pubmed.ncbi.nlm.nih.gov/42237047/). *Eur Spine J*. [Epidemiology / Natural History]
Subramanian T (2026). [PMID: 41859436](https://pubmed.ncbi.nlm.nih.gov/41859436/). *HSS J*. [Review / Meta-Analysis]
Li J (2026). [PMID: 41507621](https://pubmed.ncbi.nlm.nih.gov/41507621/). *Eur Spine J*. [Diagnostic / Biomarker]
Bae S (2026). [PMID: 41583620](https://pubmed.ncbi.nlm.nih.gov/41583620/). *J Orthop*. [Review / Meta-Analysis]
Buendía Pérez J (2026). [PMID: 42007509](https://pubmed.ncbi.nlm.nih.gov/42007509/). *Microsurgery*. [Case Report / Case Series]
AI-curated news mentioning spinal chordoma
Updated Apr 30, 2026
A new study reveals that a patient-derived organoid model demonstrates TP53-dependent sensitivity to gemcitabine in spinal chordoma. This finding could inform future treatment strategies for patients with this rare cancer.